Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

PHASE4CompletedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

September 30, 2004

Study Completion Date

October 31, 2005

Conditions
Diabetic Neuropathy, Painful
Interventions
DRUG

Pregabalin

Trial Locations (30)

12205

Pfizer Investigational Site, Albany

14618

Pfizer Investigational Site, Rochester

14642

Pfizer Investigational Site, Rochester

16635

Pfizer Investigational Site, Duncansville

27834

Pfizer Investigational Site, Greenville

33401

Pfizer Investigational Site, West Palm Beach

33407

Pfizer Investigational Site, West Palm Beach

33410

Pfizer Investigational Site, Palm Beach Gardens

33462

Pfizer Investigational Site, Lake Worth

34471

Pfizer Investigational Site, Ocala

34474

Pfizer Investigational Site, Ocala

43623

Pfizer Investigational Site, Toledo

68116

Pfizer Investigational Site, Omaha

68131

Pfizer Investigational Site, Omaha

71913

Pfizer Investigational Site, Hot Springs

75214

Pfizer Investigational Site, Dallas

75230

Pfizer Investigational Site, Dallas

75246

Pfizer Investigational Site, Dallas

77030

Pfizer Investigational Site, Houston

78229

Pfizer Investigational Site, San Antonio

80218

Pfizer Investigational Site, Denver

89102

Pfizer Investigational Site, Las Vegas

90502

Pfizer Investigational Site, Torrance

90509

Pfizer Investigational Site, Torrance

92037

Pfizer Investigational Site, La Jolla

33351-6637

Pfizer Investigational Site, Sunrise

02115

Pfizer Investigational Site, Boston

07631

Pfizer Investigational Site, Englewood

08901

Pfizer Investigational Site, New Brunswick

08903

Pfizer Investigational Site, New Brunswick

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00159679 - Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy | Biotech Hunter | Biotech Hunter